Ibudilast

CHEMBL19449 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
230.3 g/mol
LogP
3.0
Phase
4

An anti-inflammatory drug studied for multiple sclerosis and migraine, inhibiting phosphodiesterase enzymes.

Peso Molecular

230,3100 g/mol

LogP

3,00

TPSA

34,40 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)C(=O)c1c(C(C)C)nn2ccccc12

InChI

InChI=1S/C14H18N2O/c1-9(2)13-12(14(17)10(3)4)11-7-5-6-8-16(11)15-13/h5-10H,1-4H3

Molecular Formula

C14H18N2O

HBD / HBA

- / 2

Ligações Rotacionáveis

3

Átomos Pesados

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An anti-inflammatory drug studied for multiple sclerosis and migraine, inhibiting phosphodiesterase enzymes.

Yes, Ibudilast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL19449. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3671. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.